Clinical trial NCT05564845: Brain Structure and Neurocognitive Development in Sickle Cell Disease; a Longitudinal Cohort Study (BRICK Study)
Official title: Brain Structure and Neurocognitive Development in Sickle Cell Disease; a Longitudinal Cohort Study (BRICK Study)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Brain Development Abnormality
Sickle Cell Disease
Keywords: brain development
Sickle cell disease
Lead sponsor: Erasmus Medical Center
Sponsor class: OTHER
Collaborators: name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
First posted: 2022-10-04
Enrollment: 84
Sex: ALL
Minimum age (years): 6
Maximum age (years): 25
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children and adolescents diagnosed with SCD of all genotypes, treated at Erasmus MC and the Amsterdam UMC, ranging from 6 to 18 years at initiation of the study.

The clinical phenotype of SCD consists of a spectrum: From the patients with a high hemoglobin plus an absent or lower incidence of VOCs to the patients with a higher hemoglobin and a higher incidence of VOCs. We chose to include SCD patients of all genotypes, not only the HbSS and Hbẞ0 thalassemia, to cover the whole phenotypic range of SCD. This was chosen in order to infer the possible causes of an expected difference in white matter volume increase, like anemia and sickling-propensity.

Brief summary: Sickle cell disease (SCD) is an autosomal recessive red blood cell blood disorder. One especially vital organ affected in SCD is the brain. Individuals with SCD have an increased risk of both overt cerebral infarctions and silent infarctions. The latter are brain lesions without apparent neurological sequelae. Since cortical neurons in the brain lack the ability to regenerate, tissue damage accumulates throughout the already shortened lifespan of individuals with SCD, resulting in far-reaching consequences such as significant cognitive impairment. Currently, only hematological stem cell transplantation can halt the multiorgan tissue damage. However, the criteria to determine the timing of curative therapy do not center the brain, despite that subtle anomalies of this critical organ can have long-lasting consequences. Since it is not yet known whether brain tissue damage precedes, parallels, or lags behind non-brain tissue damage, it is critical to map these effects in youth with SCD. While importantly comparing images with a healthy reference population. Understanding how the brain is affected is critical for clinical decision making, such as timing of potentially curative interventions but also, to prevent long term irreversible brain damage in youth with SCD. In this study, a cohort of 84 SCD patients between the ages of 6 and 18 at baseline, will undergo MR imaging, neurological examination, neuropsychological assessment and blood sampling three times in total, with intervals of two years; results will be innovatively compared with children included in the Generation R population study (±8000 MRIs children and (young)adults) 6-20 years of age). Our hypothesis, based on the inability of the brain to generate new cortical neurons following cell death, is that brain function is impaired earlier than other organ systems and that there is an age-dependent limit in the brain's ability to remodel itself based on neuroplasticity.

Detailed description: Objective: The primary objective is to evaluate longitudinal developmental changes in brain structure in patients aged 6-18 years with SCD. The secondary objective is to analyze the longitudinal relations between biomarkers, demographic characteristics, brain structure, neurocognitive functioning, behavioral functioning and developmental changes in brain structure.

Study Design: Longitudinal cohort study (BRICK) with a duration of 4 years. Study population: Children and adolescents with sickle cell disease (SCD) of all genotypes (e.g. HbSS, HbSβº, HbSβ+, and HbSC) aged 6 -18 years. This will be compared to a cohort of healthy children and adolescents from Generation R.

Primary study endpoint:

* Total white matter volume increase in children and adolescents with SCD Secondary study endpoints
* Neurocognitive functioning (intelligence, specific neurocognitive functions, network organization)
* Incidence of stroke
* Other forms complications due to SCD
* Amount of hospital admissions, day care admissions (adult care only), crises at home, contact moments with the sickle cell center, ER visits
* Biomarkers for anemia, hemolysis, inflammation and endothelial activation.
* Behavioral functioning Nature and extent of the burden and risk associated with participation, benefit and group relatedness: By creating an advanced model for structural neurological, neurocognitive functioning in SCD, we will gain more insight into the pathophysiological origins and risk factors for SCD-related brain abnormalities. This will support development of preventive and supportive strategies as well as the initiation and evaluation of therapeutic interventions. Previous experience with the performance of brain MRI scans combined with recent research, indicates that the emotional burden placed on young children when undergoing a brain MR scan, are proportionate to the emotional burden placed on adults when they undergo a brain MR-scan. Furthermore, children will be offered the opportunity to become acquainted with the research procedure by witnessing an MRI scan session prior before participation.

Eligibility criteria: Inclusion Criteria:

* Patients with SCD of all genotype between 6 and 18 at baseline

Exclusion Criteria:

* Parents/ guardians (in case of minors) or patients themselves (\>16 years) unable to make an informed decision on participating in this study.

  * An abnormal brain MRI prior to initiation of the study due to non-SCD related causes.
  * Contraindications for brain MRI per protocol

Primary outcomes:
measure: mm3/time unit
timeFrame: 4 years
Secondary outcomes:
measure: Full scale IQ (FSIQ)
timeFrame: 4 years
measure: Incidence of stroke
timeFrame: 4 years
measure: Other forms complications due to SCD
timeFrame: 4 years
measure: Amount of hospital admissions
timeFrame: 4 years
measure: Ld, bilirubin
timeFrame: 4 years
measure: Times/year
timeFrame: 4 years
measure: Hb, Ht
timeFrame: 4 years
measure: T score metric: a score of 50 represents the mean score of a reference population and 10 is the standard deviation.
timeFrame: 4 years
Other outcomes:
Locations:
city: Rotterdam
country: Netherlands
facility: Erasmus MC
state: South Holland
city: Amsterdam
country: Netherlands
facility: Amsterdam University Medical Center
Study officials:
References: